Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OUTLOOK THERAPEUTICS, INC.

(OTLK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

OUTLOOK THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

07/30/2021 | 04:12pm EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 27, 2021, Outlook Therapeutics, Inc. (the "Company") entered into an Employment Agreement (the "Agreement") with Lawrence Kenyon, the Company's Executive Vice President and Chief Financial Officer. The Agreement supersedes Mr. Kenyon's prior Employment Agreement with the Company.

The Agreement provides for Mr. Kenyon's employment as Executive Vice President and Chief Financial Officer of the Company for a term of twelve (12) months. Mr. Kenyon will receive a base salary of $425,000, as well as a cash bonus for 2021 equal to 50% of his base salary, which shall be payable if the Company meets or exceeds certain financial and other business milestone objectives as determined and approved by the Board of Directors and the Chief Executive Officer of the Company (the "Goal Achievement"). If (i) the Company terminates Mr. Kenyon's employment without Cause (as defined in the Agreement), (ii) Mr. Kenyon terminates his employment for Good Reason (as defined in the Agreement), (iii) the term of the Agreement expires or (iv) Mr. Kenyon terminates his employment following the Goal Achievement, Mr. Kenyon will be entitled to receive an amount equal to 12 months of his base salary plus a bonus equal to 50% of his base salary, as well as the acceleration of 50% of Mr. Kenyon's unvested equity awards subject to time-based vesting requirements. In such case, Mr. Kenyon's remaining unvested equity awards will continue to vest in accordance with the applicable vesting schedule, but will not require continuous service for such vesting.

The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the Employment Agreement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits





(d) Exhibits.



Exhibit No.   Description
  10.1          Executive Employment Agreement by and between Lawrence Kenyon and
              Outlook Therapeutics, Inc, dated July 27, 2021.

© Edgar Online, source Glimpses

All news about OUTLOOK THERAPEUTICS, INC.
08:05aOUTLOOK THERAPEUTICS : to Present at the Cantor Fitzgerald Virtual Global Healthcare Confe..
AQ
09/14OUTLOOK THERAPEUTICS : Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA (..
AQ
09/13OUTLOOK THERAPEUTICS : Presents Positive NORSE THREE Safety Data foráONS-5010 / LYTENAVA&t..
AQ
09/13Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010/LYTENAVAÖ
CI
09/08OUTLOOK THERAPEUTICS : to Present at H.C. Wainwright 23rd Annual Global Investment Confere..
AQ
09/03CORPORATE PRESENTATION : September 2021
PU
08/16OUTLOOK THERAPEUTICS : Reports Financial Results for Third Quarter of Fiscal Year 2021 and..
AQ
08/13OUTLOOK THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Res..
AQ
08/13OUTLOOK THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Stat..
AQ
08/13Outlook Therapeutics Provides Clinical Development and Pre-Commercialization Update on ..
CI
More news
Financials (USD)
Sales 2021 0,42 M - -
Net income 2021 -49,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,60x
Yield 2021 -
Capitalization 405 M 405 M -
Capi. / Sales 2021 971x
Capi. / Sales 2022 174x
Nbr of Employees 8
Free-Float 52,1%
Chart OUTLOOK THERAPEUTICS, INC.
Duration : Period :
Outlook Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OUTLOOK THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 2,31 $
Average target price 7,00 $
Spread / Average Target 203%
EPS Revisions
Managers and Directors
C. Russell Trenary President, Chief Executive Officer & Director
Lawrence A. Kenyon CFO, Secretary, Treasurer & Director
Ralph H. Thurman Independent Executive Chairman
Jennifer M. Kissner Senior Vice President-Clinical Development
Terry Dagnon Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
OUTLOOK THERAPEUTICS, INC.74.62%398
MODERNA, INC.315.47%170 876
LONZA GROUP AG31.58%59 927
IQVIA HOLDINGS INC.43.03%48 510
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-5.78%28 939